Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis

被引:27
作者
Kempen, JH
Jabs, DA
Wilson, LA
Dunn, JP
West, SK
机构
[1] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21218 USA
关键词
D O I
10.1016/j.ajo.2005.01.005
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate the risk and risk factors for developing cytomegalovirus (CMV) retinitis in previously uninvolved second eyes among patients with unilateral CMV retinitis. DESIGN: Cohort study. METHODS: SETTINGS: Single center academic AIDS ophthalmology practice. PATIENT POPULATION: Three hundred seventy,six consecutive patients with AIDS and unilateral CMV retinitis were followed from the time of CMV retinitis diagnosis for the development of second-eye retinitis. EXPERIMENTAL PROCEDURES: Demographic and clinical characteristics were noted at baseline. Use of highly active antiretroviral therapy (HAART) and immune recovery in response to HAART were noted prospectively. MAIN OUTCOME MEASURE: Development of CMV retinitis in a previously uninvolved eye. 0 RESULTS: Ninety-one percent of subjects received systemic anti-CMV treatment. Second-eye retinitis occurred in 26.1% person-year (19.6% within the first 6 months), less than half the rate previously reported in untreated groups. Initial CD4+ T cell count > 12 cells/mu l, use of HAART, and initial posterior pole involvement were associated with 64%, 46%, and 41% reductions in incidence vis-A-vis comparison groups. Benefit from HAART was limited to that subset who developed immune recovery of a degree expected to restore innate control of CMV (a rise in the CD4+ T cell count by > 50 cells/mu l to a level > 100 cells/mu l). CONCLUSIONS: The risk of second-eye retiniti is substantial in patients with unilateral CMV retinitis but appears to be reduced by anti-CMV therapy and by HAART-induced immune recovery. Patients are at highest risk when CD4+ T cell counts are very low and in the months immediately after CMV retinitis diagnosis. (c) 2005 by Elsevier Inc. All rights reserved.
引用
收藏
页码:1028 / 1034
页数:7
相关论文
共 28 条
[1]  
[Anonymous], 1982, Morbidity and Mortality Weekly Report, V31, P507
[2]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[3]  
[Anonymous], 1985, Morbidity and mortality weekly report, V34, P373
[4]   Cytomegalovirus retinitis in patients with AIDS in Europe [J].
Burke, M ;
Yust, I ;
Katlama, C ;
Vardinon, N ;
Clumeck, N ;
Pinching, AJ ;
Ledergerber, B ;
Gatell, JM ;
Chiesi, A ;
Barton, SE ;
Lundgren, JD ;
Pedersen, C .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (12) :876-882
[5]  
CDC, 1982, Morbidity and Mortality Weekly Report (MMWR), V31, P507
[6]  
Centers for Disease Control and Prevention, 1987, MMWR S, V36, p1S
[7]  
Cox D. R., 1984, Analysis of survival data
[8]   INCIDENCE AND NATURAL-HISTORY OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
GALLANT, JE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CHAISSON, RE ;
BARTLETT, J ;
MCAVINUE, S ;
BRYSON, Y ;
COHEN, H ;
FISCHL, M ;
BOLIN, T ;
KESSLER, H ;
BURROUGH, Y ;
MILDVAN, D ;
FOX, A ;
RICHMAN, D ;
FREEMAN, B ;
SIMON, G ;
GRABOWY, KW ;
CHERNOFF, D ;
DUFF, P ;
THOMPSON, S ;
BARRETT, K ;
AWE, R ;
CHAPMAN, R ;
LEONARD, S ;
BAINES, L ;
TURNER, P ;
HAWKINS, M ;
MURRAY, H ;
BOWERS, J ;
LANE, C ;
TILSON, H ;
ANDREWS, E ;
SMILEY, L .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1223-1227
[9]   A CONTROLLED RETROSPECTIVE STUDY OF GANCICLOVIR TREATMENT FOR CYTOMEGALO-VIRUS RETINOPATHY - USE OF A STANDARDIZED SYSTEM FOR THE ASSESSMENT OF DISEASE OUTCOME [J].
HOLLAND, GN ;
BUHLES, WC ;
MASTRE, B ;
KAPLAN, HJ .
ARCHIVES OF OPHTHALMOLOGY, 1989, 107 (12) :1759-1766
[10]  
Holtzer CD, 1998, AIDS, V12, P1931